Farnesyl protein transferase inhibition: a novel approach to anti-tumor therapy. the discovery and development of SCH 66336.

Abstract

Farnesyl protein transferase (FPT) inhibition is an interesting and promising approach to non-cytotoxic anticancer therapy. Research in this area has resulted in several orally active compounds that are currently in clinical evaluation. This review focuses on FPT inhibitors in clinical trials and concentrates on the benzocycloheptapyridine class, with details on the discovery and development of SCH 66336, currently in Phase II clinical trials.

Cite this paper

@article{Ganguly2001FarnesylPT, title={Farnesyl protein transferase inhibition: a novel approach to anti-tumor therapy. the discovery and development of SCH 66336.}, author={Ashit K. Ganguly and Ronald J. Doll and Viyyoor M. Girijavallabhan}, journal={Current medicinal chemistry}, year={2001}, volume={8 12}, pages={1419-36} }